Paul D'Sylva

Dr Ashley Paul D'Sylva is a founding director of Empire Equity, where he has led and arranged over $500m in funding transactions since 2008 for a diverse range of resource and energy companies in equity, debt and structured financings on a proprietary basis as well as from a network of institutional funding partners. Dr D'Sylva received a PhD from the University of Arizona in Public Finance and Econometrics. He was a recipient of a Business News 40Under40 award in 2004 while he held responsibility for the management of Murdoch University’s research and the commercialisation of its intellectual property. Dr D'Sylva developed a joint venture with Westscheme Superannuation Fund to create the Murdoch-Westscheme Enterprise Fund, WA’s largest private fund under management at the time. It provided a capital pool for early-stage Murdoch University research that has strong commercial potential.
Bio last updated 17 Aug 2019

Article Timeline

Positions - Previous

PositionCompanyYearCompany's current rankWA staff
Non-Executive Director
Kaboko Mining
Kaboko Mining
2013 - 2016
Director & A/Chairman
Pluton Resources
Pluton Resources
2014 - 2016
Interim Executive Chairman
Continental Coal
2014 - 2016
Non-Executive Chairman
Alcyone Resources
Alcyone Resources
2013 - 2015
Managing Director
2005 - 200798

Directors Interests

CompanyDateTransaction typeNumber of sharesPrice per shareTransaction valueNature of change
Alcyone Resources16 Sep 2013Bought44,313,182$0.00$0OtherConversion of performance rights
Source: Morningstar

Equity Capital Markets Deals

DateCompanyTransaction TypeTotal Value
08/09/14Pluton ResourcesEntitlement offer$47.8m>>
02/07/13Alcyone ResourcesEntitlement offer$7.4m>>
31/03/14Continental CoalConvertible note issue$5.0m>>
20/01/14Alcyone ResourcesPlacement$4.9m>>
08/09/14Continental CoalEntitlement offer$4.0m>>

Mergers & Acquisitions Deals

AnnouncedBidderTargetTransaction TypeTotal Value
03/11/14LSP EnergyContinental CoalAsset acquisition$91.1m>>

Total Shareholder Return as at 31/07/19

1 year TSR5 year TSR
271stProteomics International Laboratories7%
731 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$0 Bought
Total value as at the date of the transaction
Source: Morningstar


111th↑Proteomics International Laboratories$2.1m
198 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer